Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Neuromuscular disease: acute treatment for myasthenia gravis.

Gilhus NE.

Nat Rev Neurol. 2011 Mar;7(3):132-4. doi: 10.1038/nrneurol.2011.14. No abstract available.

PMID:
21386868
2.

Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.

Minami N, Fujiki N, Doi S, Shima K, Niino M, Kikuchi S, Sasaki H.

J Neurol Sci. 2011 Jan 15;300(1-2):59-62. doi: 10.1016/j.jns.2010.09.033. Epub 2010 Oct 29.

PMID:
21035148
3.

Treatment of myasthenia gravis.

Kumar V, Kaminski HJ.

Curr Neurol Neurosci Rep. 2011 Feb;11(1):89-96. doi: 10.1007/s11910-010-0151-1. Review.

PMID:
20927659
4.

Myasthenia gravis.

Jani-Acsadi A, Lisak RP.

Curr Treat Options Neurol. 2010 May;12(3):231-43. doi: 10.1007/s11940-010-0070-0.

PMID:
20842584
5.

Acquired myasthenia gravis in childhood.

Evoli A.

Curr Opin Neurol. 2010 Oct;23(5):536-40. doi: 10.1097/WCO.0b013e32833c32af. Review.

PMID:
20581680
6.

Myasthenia gravis requiring pyridostigmine treatment in a national population cohort.

Andersen JB, Engeland A, Owe JF, Gilhus NE.

Eur J Neurol. 2010 Dec;17(12):1445-50. doi: 10.1111/j.1468-1331.2010.03089.x.

PMID:
20491896
7.

Guidelines for treatment of autoimmune neuromuscular transmission disorders.

Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW; European Federation of Neurological Societies.

Eur J Neurol. 2010 Jul;17(7):893-902. doi: 10.1111/j.1468-1331.2010.03019.x. Epub 2010 Apr 12.

PMID:
20402760
8.

Diagnostic use of autoantibodies in myasthenia gravis.

Leite MI, Waters P, Vincent A.

Autoimmunity. 2010 Aug;43(5-6):371-9. doi: 10.3109/08916930903541208. Review.

PMID:
20380582
9.

Immunosuppressive therapies in myasthenia gravis.

Sanders DB, Evoli A.

Autoimmunity. 2010 Aug;43(5-6):428-35. doi: 10.3109/08916930903518107. Review.

PMID:
20166870
10.

The incidence of myasthenia gravis: a systematic literature review.

McGrogan A, Sneddon S, de Vries CS.

Neuroepidemiology. 2010;34(3):171-83. doi: 10.1159/000279334. Epub 2010 Feb 2. Review.

PMID:
20130418
11.

Autoimmune myasthenia gravis.

Gilhus NE.

Expert Rev Neurother. 2009 Mar;9(3):351-8. doi: 10.1586/14737175.9.3.351. Review.

PMID:
19271944
12.

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.

Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg Sørensen P, Udd B; EFNS.

Eur J Neurol. 2008 Sep;15(9):893-908. doi: 10.1111/j.1468-1331.2008.02246.x. Erratum in: Eur J Neurol. 2009 Apr;16(4):547.

PMID:
18796075
13.

Lessons from two trials of mycophenolate mofetil in myasthenia gravis.

Sanders DB, Siddiqi ZA.

Ann N Y Acad Sci. 2008;1132:249-53. doi: 10.1196/annals.1405.031.

PMID:
18567876
14.

Response to therapy in myasthenia gravis with anti-MuSK antibodies.

Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, Scuderi F, Bartoccioni E.

Ann N Y Acad Sci. 2008;1132:76-83. doi: 10.1196/annals.1405.012.

PMID:
18567856
15.
16.

IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.

Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A.

Brain. 2008 Jul;131(Pt 7):1940-52. doi: 10.1093/brain/awn092. Epub 2008 May 31.

17.

Optimal therapy for thymoma.

Kondo K.

J Med Invest. 2008 Feb;55(1-2):17-28. Review.

18.

Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care.

Hoff JM, Daltveit AK, Gilhus NE.

Eur J Neurol. 2007 Jan;14(1):38-43.

PMID:
17222111
19.

Myasthenia gravis: past, present, and future.

Conti-Fine BM, Milani M, Kaminski HJ.

J Clin Invest. 2006 Nov;116(11):2843-54. Review.

20.

CDR3 spectratyping analysis of the TCR repertoire in myasthenia gravis.

Matsumoto Y, Matsuo H, Sakuma H, Park IK, Tsukada Y, Kohyama K, Kondo T, Kotorii S, Shibuya N.

J Immunol. 2006 Apr 15;176(8):5100-7.

Supplemental Content

Support Center